发作后的2-脱氧-D-葡萄糖的使用对点燃进展有疾病修饰作用
Thomas P Sutula1, Scott T Wilson2, Sheilah Franzoso1
1Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Epilepsy research
|June 1, 2023
概括
低剂量的二氧化D-葡萄糖 (2DG),一种糖解抑制剂,有效地减缓了小鼠的发作进展. 2DG在发作后的使用显示出减少发作集群和长期影响的前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 2-脱氧-D-葡萄糖 (2DG) 是一种抑制糖解的葡萄糖模拟物.
- 2DG在各种发作模型中表现出抗和抗性质.
- 之前的研究表明,2DG (250 mg/kg IP) 在刺激前给予时会延迟点燃进展,但对更高剂量的心脏毒性的担忧促使进一步调查.
研究的目的:
- 为了确定2DG是否会在低于引起心脏毒性的剂量下减缓发作进展.
- 为了评估2DG在发作后的不同时间点,包括发作后给药时的疗效.
- 评估2DG在治疗复发性发作及其后果方面的潜在临床实用性.
主要方法:
- 在老鼠中使用燃烧模型来唤起重复的发作.
- 2DG是以37.5 mg/kg的剂量通过腹腔内 (IP) 给药的.
- 给药时间包括刺激前30分钟和引起发作后的10分钟.
主要成果:
- 在IP37.5 mg/kg的2DG显著减缓了点燃进展,在刺激前30分钟给予时几乎翻了一番.
- 同一剂量2DG也在引起发作后立即和10分钟后使用时表现出有效性.
- 在毒理学研究中,这些发现的剂量远低于与心肌细胞真空化相关的剂量.
结论:
- 低剂量的2DG有效地减缓了老鼠点火模型中的发作进展.
- 2DG在后的使用代表了对集群的潜在新疗法策略.
- 对人体等效剂量的进一步研究表明,2DG可能是安全的,并且可以很好地减轻和长期并发症的负担.
相关概念视频
01:13Seizures: Classification
451
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
451
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
474
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
474
01:24Epilepsy and Seizures: Overview
230
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
230
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354